×
About 5,855 results

ALLMedicine™ Vitiligo Center

Research & Reviews  1,882 results

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Prolonged Drug-Induced Hypersensitivity Syndrome/DRESS With Alopecia Areata and Autoimmune Thyroiditis
https://www.mdedge.com/fedprac/article/256980/mixed-topics/prolonged-drug-induced-hypersensitivity-syndrome/dress-alopecia
2LT Kathleen Krivda, USA, LTC John Campagna, MD, USA et. al.

Aug 11th, 2022 - Drug-induced hypersensitivity syndrome (DIHS), also called drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a potentially fatal drug-induced hypersensitivity reaction that is characterized by a cutaneous eruption, multior.

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04927975

Aug 5th, 2022 - Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adve...

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Aug 5th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment
https://clinicaltrials.gov/ct2/show/NCT04738149

Aug 5th, 2022 - The purpose of this research is to treat vitiligo with a topical PGF2α, microneedling and excimer laser. The goal is to have greater repigmentation than the standard of care (excimer) after 12 weeks of treatment. The study is a pilot, split study ...

see more →

Guidelines  1 results

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  194 results

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04927975

Aug 5th, 2022 - Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adve...

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Aug 5th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment
https://clinicaltrials.gov/ct2/show/NCT04738149

Aug 5th, 2022 - The purpose of this research is to treat vitiligo with a topical PGF2α, microneedling and excimer laser. The goal is to have greater repigmentation than the standard of care (excimer) after 12 weeks of treatment. The study is a pilot, split study ...

Daily Topical Rapamycin for Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05342519

Aug 4th, 2022 - In current Dermatology practice, options for vitiligo remain limited. The purpose of this study is to determine if once daily dosed topical rapamycin is effective for the treatment of patients with vitiligo. Participants will apply either 0.1% top...

Effect of Alpha-lipoic Acid on Regression of Low-grade Squamous Intraepithelial Lesions (LSIL)
https://clinicaltrials.gov/ct2/show/NCT05485259

Aug 3rd, 2022 - Cervical intraepithelial neoplasia (CIN) is premalignant change on the cervix that can lead to malignant changes, i.e., cervical cancer. Today, this term has been replaced by the more recent term squamous intraepithelial lesion (SIL). With the int...

see more →

News  249 results

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Prolonged Drug-Induced Hypersensitivity Syndrome/DRESS With Alopecia Areata and Autoimmune Thyroiditis
https://www.mdedge.com/fedprac/article/256980/mixed-topics/prolonged-drug-induced-hypersensitivity-syndrome/dress-alopecia
2LT Kathleen Krivda, USA, LTC John Campagna, MD, USA et. al.

Aug 11th, 2022 - Drug-induced hypersensitivity syndrome (DIHS), also called drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a potentially fatal drug-induced hypersensitivity reaction that is characterized by a cutaneous eruption, multior.

Dermatologists Share Vitiligo Breakthrough News With Patients
https://www.medscape.com/viewarticle/978705

Aug 5th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a US Food and Drug Administration (FDA)-approved, easy-to-use to...

Topical Ruxolitinib Quickly Relieves Atopic Dermatitis Itch in Black Patients
https://www.medscape.com/viewarticle/978653

Aug 4th, 2022 - Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream monotherapy over 8 weeks was associated with rapid and c...

FDA Approves Topical Ruxolitinib (Opzelura) for Nonsegmental Vitiligo
https://www.medscape.com/viewarticle/977464

Jul 19th, 2022 - The US Food and Drug Administration has approved topical ruxolitinib (Opzelura) for the treatment of nonsegmental vitiligo in patients aged 12 years or older, the manufacturer, Incyte, announced on July 18. The treatment, which was approved for tr...

see more →

Patient Education  8 results see all →